

2

Docket No. GJE-70
Serial No. 09/868,352In the Claims

Claims 1-30 (Cancelled)

Claim 31 (Currently amended): A method for the treatment of a condition associated with bacterial Group B Streptococcal infection, wherein said method comprises administering to a patient in need of such treatment; an effective amount of a peptide encoded by a polynucleotide sequence; wherein said polynucleotide sequence comprises SEQ ID NO:22, or a homologue or functional fragment thereof, wherein said homologue is obtainable from a Group B *Streptococcus* and has at least 60% sequence similarity to SEQ ID NO:22 comprising the amino acid sequence of SEQ ID NO:23, or an immunogenic portion thereof, wherein the immunogenic portion elicits a protective immune response against Group B *Streptococcus*, and wherein the immune response recognizes the full-length amino acid sequence of SEQ ID NO:23.

Claim 32 (Cancelled)

Claim 33 (Previously added): The method according to claim 31, wherein said peptide comprises the amino acid sequence of SEQ ID NO:23.

Claim 34 (Cancelled)

Claim 35 (Previously added): The method according to claim 31, wherein the infection is a local infection.

Claim 36 (Previously added): The method according to claim 31, wherein the infection is a urinary tract infection.

J:\GJE70\Amend-Resp\Resp AF.doc\DNB/mv

3

Docket No. GJE-70
Serial No. 09/868,352

Claim 37 (Currently amended): A method for the prevention of a condition associated with bacterial Group B Streptococcal infection, wherein said method comprises administering to a patient in need of such prevention; an effective amount of a peptide encoded by a polynucleotide sequence; wherein said polynucleotide sequence comprises SEQ ID NO:22, or a homologue or functional fragment thereof; wherein said homologue is obtainable from a Group B Streptococcus and has at least 60% sequence similarity to SEQ ID NO:22 comprising the amino acid sequence of SEQ ID NO:23, or an immunogenic portion thereof, wherein the immunogenic portion elicits a protective immune response against Group B Streptococcus, and wherein the immune response recognizes the full-length amino acid sequence of SEQ ID NO:23.

Claim 38 (Cancelled)

Claim 39 (Previously added): The method according to claim 37, wherein said peptide comprises the amino acid sequence of SEQ ID NO:23.

Claim 40 (Cancelled)

Claim 41 (Previously added): The method according to claim 37, wherein the infection is a local infection.

Claim 42 (Previously added): The method according to claim 37, wherein the infection is a urinary tract infection.

J:\GJE\70\Amend-Resp\Resp AF.doc/DNB/mv